Influenza A and B remain common causes of seasonal respiratory infections. We are pleased to share the performance of Cnpair’s Flu A/B Antibodies raw materials, designed to support the development of high-quality immunoassays, especially lateral flow (LF) assays. Key performance highlights include:
1️⃣No cross-reactivity between Flu A/B
2️⃣Excellent specificity against 20 common interferents
3️⃣High detection sensitivity
Internal Validation Data
* Sample Source：2nd National Reference Panel for Influenza A/B Viral Antigens Detection Kit
· No Cross-Reactivity
Cnpair’s Flu A/B combination test card showed no detectable cross-reactivity between Flu A and Flu B, demonstrating excellent specificity.
| Content | Pathogen | Detection line | Cnpair test result |
|---|---|---|---|
| Positive reference | B/Yamagata | A | – |
| B | 4 | ||
| B/Yamagata | A | – | |
| B | 2.5 | ||
| B/Victoria | A | – | |
| B | 5 | ||
| B/Victoria | A | – | |
| B | 6 | ||
| 2009 H1N1 | A | 7 | |
| B | – | ||
| 2009 H1N1 | A | 2.5 | |
| B | – | ||
| Seasonality H1N1 | A | 2.5 | |
| B | – | ||
| Influenza A H3N2 | A | 6 | |
| B | – | ||
| Influenza A H3N2 | A | 5 | |
| B | – | ||
| Influenza A H7N9 | A | 5 | |
| B | – |
Colloidal gold colorimetric test score card
· Specificity Performance
Cnpair’s Flu A/B combination test cards demonstrated excellent specificity when evaluated against 20 common pathogens and medications, with no visible signals observed in any of the tests.
| Content | Pathogen | Detection line | Cnpair test result |
|---|---|---|---|
| Negative reference | Staphylococcus aureus | A | – |
| B | – | ||
| Streptococcus pneumoniae | A | – | |
| B | – | ||
| Measles virus | A | – | |
| B | – | ||
| Mumps virus | A | – | |
| B | – | ||
| Adenovirus type 3 | A | – | |
| B | – | ||
| Adenovirus type 7 | A | – | |
| B | – | ||
| Mycoplasma pneumoniae | A | – | |
| B | – | ||
| Parainfluenza type 2 | A | – | |
| B | – | ||
| Metapneumovirus | A | – | |
| B | – | ||
| Coronavirus OC43 | A | – | |
| B | – | ||
| Coronavirus 229E | A | – | |
| B | – | ||
| Bacillus pertussis | A | – | |
| B | – | ||
| Epstein-barr virus | A | – | |
| B | – | ||
| Enterovirus CA16 | A | – | |
| B | – | ||
| Respiratory syncytial virus | A | – | |
| B | – | ||
| Rhinovirus group A | A | – | |
| B | – | ||
| Neisseria meningitidis | A | – | |
| B | – | ||
| COVID-19 Omicron | A | – | |
| B | – | ||
| Negative swab | A | – | |
| B | – | ||
| Dexamethasone sodium phosphate, 0.4mg/mL | A | – | |
| B | – |
· LoD Performance
Validated with the National Reference Panel, Cnpair’s Flu A/B combination test cards achieved 100% detection on LF, demonstrating excellent sensitivity across different Influenza A and B subtypes.
| Content | ID | Pathogen | Specified detection concentration（U/mL） |
|---|---|---|---|
| Limit of Detection | L1 | 2009 H1N1 | 1.3×10⁵ |
| L2 | Seasonality H1N1 | 2.7×10⁵ | |
| L3 | B/Victoria | 1.7×10⁵ | |
| L4 | B/Yamagata | 1.9×10⁵ | |
| L5 | H3N2 | 2.3×10⁵ | |
| L6 | H7N9 | 2.9×10⁵ |
Whether you are developing a new product or optimizing the performance of an existing one, our Flu A/B antibody portfolio can provide a reliable foundation for your diagnostic development.
See the difference? Try a sample.